Sutro's STRO-001 receives Orphan Drug designation for treatment of multiple myeloma

|About: Sutro Biopharma, Inc. (STRO)|By:, SA News Editor

The FDA grants Orphan Drug Designation to Sutro Biopharma's (NASDAQ:STRO) STRO-001 for the treatment of multiple myeloma.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

STRO-001 is an antibody drug conjugate targeting CD74, a protein highly expressed in B-cell malignancies such as multiple myeloma.

Subscribe for full text news in your inbox